ArticleEuropean journal of nuclear medicine and molecular imaging2016
Influence of (18)F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma.
Article in European journal of nuclear medicine and molecular imaging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma.The Cochrane database of systematic reviews · 2019Pooled it
- Impact ofEuropean journal of nuclear medicine and molecular imaging · 2017Trial
- Beyond target lesions: Prognostic value of longitudinal AI-derived whole-body [European journal of nuclear medicine and molecular imaging · 2026Article
- Precision medicine in cutaneous melanoma-A comprehensive review.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Review
- Evidence of 18 F-FDG Utility in Rare Case of Metastatic Anal Melanoma With Prolonged Survival.Clinical nuclear medicine · 2025Article
- Can physiologic colonic [European journal of nuclear medicine and molecular imaging · 2023Article
- The Evolution of the Sentinel Node Biopsy in Melanoma.Life (Basel, Switzerland) · 2023Review
- Article
- Considering Computational Mathematics IGHG3 as Malignant Melanoma Is Associated with Immune Infiltration of Malignant Melanoma.BioMed research international · 2022Article
- Utility of PET/CT in patients with stage I-III melanoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020Article
- Evaluation of planar bioluminescence imaging and microPET/CT for therapy monitoring in a mouse model of pigmented metastatic melanoma.American journal of nuclear medicine and molecular imaging · 2018Article
- The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy.European journal of nuclear medicine and molecular imaging · 2017Review
- Dendrimer-based contrast agents for PET imaging.Drug delivery · 2017Review
- The role of FDG-PET/CT in preoperative staging of sentinel lymph node biopsy-positive melanoma patients.EJNMMI research · 2016Article
- Anorectal malignant melanoma: curative abdominoperineal resection: patient selection with 18F-FDG-PET/CT.World journal of surgical oncology · 2016Article
- Diagnostic performance ofWorld journal of nuclear medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the influence of (18)F-FDG PET/CT in comparison to CT alone on treatment decisions in patients with advanced melanoma and to analyse the 5-year survival data in comparison to literature data.
methodsTherapy management in 64 consecutive patients (primary staging n = 52; surveillance n = 12) with stage III/IV melanoma who underwent (18)F-FDG PET/CT between 2004 and 2005 in our department was retrospectively analysed. Treatment decisions were made by two dermatooncologists for each patient twice, first based on the CT results and then based on the PET/CT results. Therapy changes based on the PET/CT results were classified as "major" (e.g. change from metastasectomy to systemic therapy) or "minor" (e.g. change from first to second line chemotherapy). The 5-year survival data of different patient cohorts were calculated.
resultsIn the 52 patients in the primary staging group, the results of (18)F-FDG PET/CT led to therapy change in 59% and a major therapy change in 52%. (18)F-FDG PET/CT led to the avoidance of futile operations in 13 patients with suspicious lesions on CT that were deemed nontumorous on PET/CT. In the 12 patients in the surveillance group, the results of (18)F-FDG PET/CT led to therapy change in 33% and a major change in 17%. The 5-year survival rates were 30% in the entire cohort, 34% in the primary staging group, and 17% in the surveillance group. A significant overall survival benefit was observed in patients in whom (18)F-FDG PET/CT excluded metastases or in whom metastases could be completely removed compared with patients who were not eligible for surgery (41% vs. 10%).
conclusionPrimary staging of patients with stage III/IV melanoma should be performed with (18)F-FDG PET/CT, leading to higher diagnostic accuracy and enabling individualized therapeutic management, especially optimal patient selection for metastasectomy. This strategy may extend long-term survival even in patients with advanced disease.
Indexed as
Identifiers
26384681What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.